Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT05327114Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of nipocalimab in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Janssen Pharmaceutical. Started Sep 2022; status: recruiting.
02
Drugs
nipocalimab
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT05327114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327114.